All the latest about our company
sFIDA Technology Reveals New Insights into Protein Aggregation in Psychotic Disorders
September 5, 2023In a pioneering study that could have wide-reaching implications for psychiatric research, scientists have employed attyloid’s surface-based Fluorescence Intensity Distribution ...
attyloid’s sFIDA Technology Key in Revealing COVID-19’s Potential Neurodegenerative Impact
August 21, 2023A new study has utilized attyloid's cutting-edge Single Molecule Fluorescence Intensity Distribution Analysis (sFIDA) technology to explore how COVID-19 may ...
Recent Study Validates Alzheimer’s Treatment in Beagle Models, Credits sFIDA Technology for Precise Quantification of Tau Aggregates
July 29, 2023In a significant new study focusing on Alzheimer's Disease (AD), researchers have highlighted the disease-modifying effects of RD2, a potential ...
New Publication Highlights Enhancement of attyloid’s sFIDA Technology Through Internal Quality Control Standards
May 10, 2023attyloid's recent publication has outlined the establishment of an internal quality control (IQC) standard aimed at improving the robustness of ...
Meet us at Neuro 4D
April 21, 2023The Neuro4D conference takes place in Mainz, Germany on May 15-16, 2023. With a focus on drug discovery for proteopathic ...
attyloid’s sFIDA Used in Detecting Parkinson’s-Related Biomarkers in Stool Samples
February 2, 2023A recent study published in Nature Parkinson’s Diease has used attyloid's sFIDA technology to measure α-synuclein aggregates in stool, a ...